FDA clears Pfizer’s potential eczema blockbuster
Pfizer’s Eucrisa has been cleared by the US Food and Drug Administration as a treatment for mild to moderate atopic dermatitis in patients two years of age and older.
Read More
Tag: Eucrisa
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
